Subacute cutaneous lupus erythematosus (SCLE) is a variant of lupus erythematosus (LE) in which cutaneous symptoms in the form of annular, scaling plaques on sun-exposed areas are the main feature. This form of lupus is frequently seen as an adverse reaction to a variety of medications. The most commonly implicated drugs are thiazides, but SCLE may also be induced by other medications such as antifungal agents, angiotensin-converting enzyme inhibitors, statins, calcium channel blockers, and tumor necrosis factor antagonists.1 Herein we report a case of SCLE induced by monotherapy with capecitabine, a 5-fluorouracil prodrug.
Fernandes NF, Rosenbach M, Elenitsas R, Kist JM. Subacute Cutaneous Lupus Erythematosus Associated With Capecitabine Monotherapy. Arch Dermatol. 2009;145(3):340–341. doi:10.1001/archdermatol.2008.619
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: